EHA 2025 | The importance of considering patient perspectives when managing CLL

We are in a very fortunate position at the moment that we have got lots of treatment choices for patients with CLL and where we’ve got lots of choices available it’s important that we bring the patient into the discussion about what is the best option for the patient in front of us. So there’s different factors that we take into consideration in choosing the best treatment for the patient. Of course, we look at the efficacy data based on the disease characteristics, so IGHV status, TP53 status. There’s patient characteristics that we also need to take into consideration as well, so what other medical problems they have, what other medication they’re on. But then the third and very important thing is what is the patient preference for the different treatment options that we’ve got? And we know from various studies where patients have been surveyed and also from discrete choice experiments that the majority of patients would prefer fixed-duration therapies where they will take treatment for a period of time, but then have a time off treatment where they don’t have to be constantly reminded of their disease by taking tablets every day. Now, of course, not every patient feels that way, and some patients prefer the security of having a continuous therapy, that they feel that something is continuously being done for their disease. And so it is a very individual approach. It can take time talking about the different options for patients, but it is an important thing when discussing the treatment options to bring the patient involved in what’s the best treatment option for them.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.